Heart drug shows promise in stopping AFib's return after ablation
NCT ID NCT06528262
First seen May 14, 2026 · Last updated May 14, 2026
Summary
This study tests whether a drug called Enavogliflozin, currently used for diabetes, can prevent atrial fibrillation (an irregular heartbeat) from returning after a catheter ablation procedure in people who also have heart failure. About 390 adults will be randomly assigned to receive either the drug or a placebo, and their heart rhythms will be monitored for one year. The goal is to see if this medication can reduce the chance of the heart rhythm problem coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Severance Hospital
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.